MyoKardia (MYOK) Receives $66.67 Average Target Price from Analysts

Shares of MyoKardia (NASDAQ:MYOK) have been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $66.67.

MYOK has been the topic of several research analyst reports. Cowen reiterated a “buy” rating and set a $56.00 price target on shares of MyoKardia in a research note on Friday, March 9th. BidaskClub upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday, March 26th. Credit Suisse Group restated an “outperform” rating and issued a $60.00 price objective on shares of MyoKardia in a research note on Thursday, January 18th. Wells Fargo restated an “outperform” rating and issued a $70.00 price objective on shares of MyoKardia in a research note on Friday, April 13th. Finally, Wedbush lifted their price objective on shares of MyoKardia from $51.00 to $69.00 and gave the company an “outperform” rating in a research note on Friday, March 9th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MYOK opened at $49.60 on Thursday. MyoKardia has a 12 month low of $12.10 and a 12 month high of $62.83.



MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.20. MyoKardia had a negative net margin of 204.48% and a negative return on equity of 24.58%. The firm had revenue of $5.60 million for the quarter, compared to analyst estimates of $5.63 million. analysts expect that MyoKardia will post -1.35 earnings per share for the current year.

In other MyoKardia news, insider Anastasios Gianakakos sold 5,000 shares of MyoKardia stock in a transaction on Monday, February 26th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the transaction, the insider now directly owns 79,390 shares in the company, valued at $4,763,400. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 19,164 shares of company stock worth $1,038,566. 33.40% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. Handelsbanken Fonder AB boosted its holdings in shares of MyoKardia by 86.7% in the fourth quarter. Handelsbanken Fonder AB now owns 28,000 shares of the biotechnology company’s stock valued at $1,179,000 after acquiring an additional 13,000 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of MyoKardia in the fourth quarter valued at about $384,000. Iguana Healthcare Management LLC purchased a new stake in shares of MyoKardia in the fourth quarter valued at about $2,105,000. Jane Street Group LLC purchased a new stake in shares of MyoKardia in the fourth quarter valued at about $213,000. Finally, Millennium Management LLC purchased a new stake in shares of MyoKardia in the fourth quarter valued at about $20,661,000. 83.49% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/04/22/myokardia-myok-receives-66-67-average-target-price-from-analysts.html.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Analyst Recommendations for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply